PALO ALTO, Calif., Nov. 16, 2017 /PRNewswire/ -- Varian Medical
Systems (NYSE: VAR) today announced it has received Shonin approval
from the Japanese Ministry of Health, Labor and Welfare (MHLW) to
market in Japan the Varian
Halcyon™ system, its new device for cancer treatment.
Halcyon simplifies and enhances virtually every aspect of
image-guided volumetric intensity modulated radiotherapy
(IMRT).
"Since its introduction just a few months ago, Halcyon has
received an enthusiastic response from clinicians around the world
and we are pleased that it is now available in Japan," said Kolleen
Kennedy, president of Varian's Oncology Systems business.
"The main goal of the Halcyon development was to increase the
availability of cost-effective advanced cancer care worldwide.
Achieving Shonin approval is an important milestone in realizing
this goal."
Halcyon is an advanced system that was designed to improve
patient comfort, simplify operations, and shorten the time from
installation to first treatment without sacrificing quality.
Patients benefit from its quiet operating environment, which is up
to 2x quieter than other systems. Additionally, Halcyon has a low
couch height for easy patient access, and soft indirect ambient
lighting in the gantry opening.
Featuring a 100cm gantry opening, which is larger than those on
standard CT machines, Halcyon is capable of rotations 4x faster
than c-arm gantries for rapid imaging and treatment. The system is
also capable of fast and sharp volumetric imaging in as little as
15 seconds. With Halcyon treatments, a complex image guided IMRT
plan is clinically accelerated compared to those delivered on
traditional devices.
To support the gantry rotation speed, while also delivering the
treatment dose precisely to the targeted area, Halcyon features a
patented dual-layer multi-leaf collimator (MLC), an innovative new
technology. Moving twice as fast as traditional MLCs, the Halcyon
MLC has a "stacked and staggered" design that enables advanced
treatment techniques. The unique capabilities of the system provide
a pathway to adaptive radiotherapy as well as opportunities for
research into new treatment protocols
Operationally, Halcyon features a streamlined workflow that only
requires nine steps from the start to the end of treatment compared
to up to more than 30 steps with older technologies. Halcyon is
well suited to treat a majority of cancer patients, offering
advanced treatments for prostate, breast, head & neck, and many
other forms of cancer.
For more information on Halcyon visit
www.varian.com/halcyon.
About Varian Medical Systems
Varian Medical Systems
focuses energy on saving lives and is the world's leading
manufacturer of medical devices and software for treating and
managing cancer. Headquartered in Palo
Alto, California, Varian employs approximately 6,600 people
around the world. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact
Mark Plungy
Varian Medical Systems
+1 (650) 424-5630
mark.plungy@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-halcyon-treatment-system-receives-shonin-approval-300556770.html
SOURCE Varian Medical Systems